Investor Research Report on Novavax, Inc. (NASDAQ:NVAX)

stock overview

Novavax, Inc. (NASDAQ:NVAX) Develops Vaccines That Improve Current Preventive Options For Avian Influenza And Other Infectious Diseases. Belonging to the Medical sector which surged 0.97% and closed its last trading session at $2.08.

The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 11/14/2016. Currently, the stock has a 1 Year Price Target of $6.74.

The consensus recommendation, according to Zacks Investment research, is 2.67. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.4 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.33 and 1.33 respectively.

Novavax, Inc. on 6/30/2016 reported its EPS as $-0.29 with the analysts projecting the EPS of the stock as $-0.25. The company beat the analyst EPS Estimate with the difference of $-0.04. This shows a surprise factor of -16%.

Many analysts have provided their estimated foresights on Novavax, Inc. Earnings, with 8 analysts believing the company would generate an Average Estimate of $-0.26. Whereas they predicted High and Low Earnings Estimate as $-0.23 and $-0.29 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.12.

Analysts are also projecting an Average Revenue Estimate for Novavax, Inc. as $4.02 Million in the Current Quarter. This estimate is provided by 7 analysts. The High Revenue estimate is predicted as 5 Million, while the Low Revenue Estimate prediction stands at 2 Million. The company’s last year sales total was 6.52 Million.

For the Current Quarter, the growth estimate for Novavax, Inc. is -116.7%, while for the Next Quarter the stock growth estimate is 13.8%. In the past 5 years, the stock showed growth of 0% per annum. While for the next 5 years, the growth estimate is 0%.

The Company got Downgrade by Citigroup on 16-Sep-16 from Buy to Neutral.

Insider Trades for Novavax, Inc. show that the latest trade was made on 21 Sep 2016 where Trizzino (John J), the Officer completed a transaction type “Buy” in which 46000 shares were traded at a price of $2.17.

11 Insider Sales transactions were made totaling 5119660 shares traded.

7 analysts projected Price Targets for Novavax, Inc. The analysts believe that the company stock price could grow as high as $14.15. The Low Price target projection by analysts is $1 and the Mean Price Target is $6.74.

Novavax, Inc. (NASDAQ:NVAX) has the market capitalization of $558.6 Million. The company rocked its 52-Week High of $9.23 on Dec 2, 2015 and touched its 52-Week Low of $1.16 on Sep 16, 2016. The stock has Return on Assets (ROA) of -56.3 percent. Return on Equity (ROE) stands at -112.4% and Return on Investment (ROI) of -53.6 percent.

The stock is currently showing YTD performance of -75.21 Percent. The company has Beta Value of 1.58 and ATR value of 0.54. The Weekly and Monthly Volatility stands at 9.90% and 10.31%.

Company profile:

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.